Dr. Crystal S. Denlinger, MD

Dr. Denlinger practices at Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Denlinger's NPI, 1063626190, was assigned on May 9, 2007. Dr. Denlinger graduated from Rutgers New Jersey Medical School in 2001. Dr. Denlinger holds Pennsylvania license MD424594.

Dr. Denlinger's primary practice is Fox Chase Cancer Center, at 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Denlinger's primary practice is Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University. Dr. Denlinger is also affiliated with Temple University Hospital. The medical group on file is Temple Faculty Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Denlinger practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Denlinger's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Denlinger is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Denlinger's licenses on file in 2 states: Pennsylvania and New York.

CMS data shows 13 Medicare services from Dr. Denlinger across 1 procedure code in 2024, all of them office visits, for 12 Medicare patients. Medicare paid $729 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 12 Medicare patients who saw Dr. Denlinger in 2024. The largest group is 85 and over, with 0 patients. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Denlinger's median patient age at 73, with 60% women.

In 2024, Dr. Denlinger wrote 24 Medicare Part D claims. 88% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $148 in total drug cost. In 2020, CMS named 167 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Denlinger for performance year 2024, reported as part of a group. Dr. Denlinger accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 140 papers to Dr. Denlinger, published from 2009 to 2025. 2020 was the busiest year, with 14. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Survivors and Adenocarcinoma. Dr. Denlinger has published most often in J Natl Compr Canc Netw. Dr. Denlinger's most frequent co-authors are Michelle Elizabeth Melisko, MD, Kevin Scott Baker, MD and Jennifer A. Ligibel, MD.

Dmand AI links Dr. Denlinger to 20 clinical trials, 7 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Liver Neoplasms, Rectal Neoplasms and Stomach Neoplasms. Fox Chase Cancer Center sponsors the most, 4. Open Payments lists research payments to Dr. Denlinger that name 1 trial.

CMS Open Payments shows 98 general payments to Dr. Denlinger from 15 drug and device companies from 2016 to 2020. Consulting fees make up the largest share, 78% of the total. Eli Lilly and Company paid the most, $16,377. It also lists 1 research payment totaling $401 in 2016, naming 1 clinical trial.

Dmand AI lists 2 awards for Dr. Denlinger, most recently CMS Stage 1 EHR in 2013. Dr. Denlinger serves on NCCN Survivorship Guidelines Panel and Chemotherapy subcommittee NCCN Esophagogastric Cancers Guidelines Panel.

Dr. Denlinger graduated from Rutgers New Jersey Medical School in 2001. Dr. Denlinger is a member of ACP and ASCO.

Dr. Denlinger is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.